US PEPFAR renewed for AIDS, TB and malaria

3 August 2008

US President George W Bush has signed a major new piece of legislation on global AIDS, tuberculosis and malaria, but Congress is not providing the money to implement it for fiscal year 2009, according to the Global AIDS Alliance. Paul Zeitz, the group's executive director, said that, while the formal approval is "deeply appreciated," he warned that, "in terms of funding, it appears to be more rhetoric than reality. Congress should make sure the program is fully funded on day one, since without the money we cannot save more lives."

The President's Emergency Plan for AIDS Relief has received praise for its success in getting antiretroviral drugs to people in less-developed countries (Marketletters passim). Critics oppose the insistence that some funds are allocated to abstinence-based HIV/AIDS preventative education and the use of branded drugs, although more generic products have been used recently.

The bill authorized $48.0 billion for global health programs. Pres Bush's original proposal, for $30.0 billion, would have kept funding at the current level. Democrat Representatives and Senators, who control a majority in both Houses of Congress, have approved far lower spending levels than requested by the Republican administration. Previously, it had been a group of Republican Senators who had tried to stop spending on the PEPFAR program reaching $10.0 billion a year, including expansion of its remit to include malaria and tuberculosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight